121 related articles for article (PubMed ID: 1776283)
21. Serum MCA, CA 125 and CA 19.9 determination in primary breast cancer.
Yenisey C; Güner G
Biochem Soc Trans; 1996 May; 24(2):302S. PubMed ID: 8736960
[No Abstract] [Full Text] [Related]
22. [Tumor markers in the diagnosis and prognosis of breast cancer].
Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
[TBL] [Abstract][Full Text] [Related]
23. [Value of interleukin-8 determination in diagnosis of benign and malignant breast tumor].
Zakrzewska I; Kozłowski L; Wojtukiewicz M
Pol Merkur Lekarski; 2002 Oct; 13(76):302-4. PubMed ID: 12557436
[TBL] [Abstract][Full Text] [Related]
24. Prognostic markers in node-negative breast cancer: a prospective study.
Kute TE; Russell GB; Zbieranski N; Long R; Johnston S; Williams H; Stackhouse C; Wilkins L; Evans I; Berry P; Rimmer K; Tucker E
Cytometry B Clin Cytom; 2004 May; 59(1):24-31. PubMed ID: 15108167
[TBL] [Abstract][Full Text] [Related]
25. Assessing the risk of recurrence in breast cancer.
Ingle JN
N Engl J Med; 1990 Feb; 322(5):329-31. PubMed ID: 2296275
[No Abstract] [Full Text] [Related]
26. [Considerations in rational use of tumor markers in breast carcinoma].
Crombach G
Praxis (Bern 1994); 1998 Apr; 87(17):589-94. PubMed ID: 9623326
[TBL] [Abstract][Full Text] [Related]
27. [Possibilities and goals in after care of breast cancer].
Seifert M; Adler A; Obermair A; Hartmann B; Denison U; Kubista E; Sevelda P
Gynakol Rundsch; 1991; 31 Suppl 2():309-11. PubMed ID: 1665141
[No Abstract] [Full Text] [Related]
28. Cancer associated serum antigen (CASA) levels in patients with breast carcinoma and in 3 control groups without breast cancer.
Meisel M; Weise J; Schwesinger G; Straube W
Arch Gynecol Obstet; 1998; 261(3):159-62. PubMed ID: 9651660
[TBL] [Abstract][Full Text] [Related]
29. Surveillance in the management of the cancer patient with special reference to breast and colon cancer.
Gardner B
Am J Surg; 1997 Feb; 173(2):141-4. PubMed ID: 9074382
[TBL] [Abstract][Full Text] [Related]
30. [Diagnostic immunohistochemistry of breast epithelial lesions].
Balaton AJ; Guinebretière JM; Penault-Llorca F
Ann Pathol; 2003 Dec; 23(6):570-81. PubMed ID: 15094595
[TBL] [Abstract][Full Text] [Related]
31. The role of cytology in differentiation of breast lesions.
Ranieri E; Virno F; D'Andrea MR; Carico E; D'Alessio A; Bergomi S; Vecchione A
Anticancer Res; 1995; 15(2):607-11. PubMed ID: 7763045
[TBL] [Abstract][Full Text] [Related]
32. False elevation of serum CA 15-3 levels in patients under follow-up for breast cancer.
Aguiar-Bujanda D; Bohn-Sarmiento U; Aguiar-Morales J
Breast J; 2004; 10(4):375-6. PubMed ID: 15239804
[No Abstract] [Full Text] [Related]
33. The epidemiology of tumor markers in breast cancer management: prognostic markers.
Page DL
Cancer Epidemiol Biomarkers Prev; 1994 Mar; 3(2):101-4. PubMed ID: 8049630
[No Abstract] [Full Text] [Related]
34. [Methodological approaches to quantitative immunohistochemical evaluation of expression of breast apoptosis and proliferation markers].
Kostiuchek IN; Kogan IIu; Kvetnoĭ IM
Arkh Patol; 2006; 68(1):47-8. PubMed ID: 16544540
[TBL] [Abstract][Full Text] [Related]
35. Serological tumor markers for monitoring breast cancer.
Sölétormos G
Dan Med Bull; 2001 Nov; 48(4):229-55. PubMed ID: 11767127
[No Abstract] [Full Text] [Related]
36. Quantitative analysis of c-erbB-2 protein in breast cancer tissue by enzyme immunoassay.
Narita T; Funahashi H; Satoh Y; Imai T; Takagi H
Jpn J Clin Oncol; 1994 Apr; 24(2):74-8. PubMed ID: 7908994
[TBL] [Abstract][Full Text] [Related]
37. [Diagnosis of the site and extent of breast carcinoma].
Kessler M; Milz P; Sittek H; Schnarkowski P; Schmidt D; Bredl T; Reiser M
Aktuelle Radiol; 1995 Jan; 5(1):47-52. PubMed ID: 7888430
[TBL] [Abstract][Full Text] [Related]
38. [A case of recurrent breast cancer for which NSE was a useful tumor marker].
Takise A; Takagi H; Abe T
Nihon Gan Chiryo Gakkai Shi; 1988 Jan; 23(1):79-83. PubMed ID: 3379335
[No Abstract] [Full Text] [Related]
39. Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study.
Bahl M; Ennis M; Tannock IF; Hux JE; Pritchard KI; Koo J; Goodwin PJ
Breast Cancer Res Treat; 2005 Nov; 94(2):135-44. PubMed ID: 16261412
[TBL] [Abstract][Full Text] [Related]
40. [Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group].
Basuyau JP; Blanc-Vincent MP; Bidart JM; Daver A; Deneux L; Eche N; Gory-Delabaere G; Pichon MF; Riedinger JM
Bull Cancer; 2000 Oct; 87(10):723-37. PubMed ID: 11084536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
